Combining MR Imaging, Positron-Emission Tomography, and CSF Biomarkers in the Diagnosis and Prognosis of Alzheimer Disease

BACKGROUND AND PURPOSE: Different biomarkers for AD may potentially be complementary in diagnosis and prognosis of AD. Our aim was to combine MR imaging, FDG-PET, and CSF biomarkers in the diagnostic classification and 2-year prognosis of MCI and AD, by examining the following: 1) which measures are most sensitive to diagnostic status, 2) to what extent the methods provide unique information in diagnostic classification, and 3) which measures are most predictive of clinical decline. MATERIALS AND METHODS: ADNI baseline MR imaging, FDG-PET, and CSF data from 42 controls, 73 patients with MCI, and 38 patients with AD; and 2-year clinical follow-up data for 36 controls, 51 patients with MCI, and 25 patients with AD were analyzed. The hippocampus and entorhinal, parahippocampal, retrosplenial, precuneus, inferior parietal, supramarginal, middle temporal, lateral, and medial orbitofrontal cortices were used as regions of interest. CSF variables included Aβ42, t-tau, p-tau, and ratios of t-tau/Aβ42 and p-tau/Aβ42. Regression analyses were performed to determine the sensitivity of measures to diagnostic status as well as 2-year change in CDR-SB, MMSE, and delayed logical memory in MCI. RESULTS: Hippocampal volume, retrosplenial thickness, and t-tau/Aβ42 uniquely predicted diagnostic group. Change in CDR-SB was best predicted by retrosplenial thickness; MMSE, by retrosplenial metabolism and thickness; and delayed logical memory, by hippocampal volume. CONCLUSIONS: All biomarkers were sensitive to the diagnostic group. Combining MR imaging morphometry and CSF biomarkers improved diagnostic classification (controls versus AD). MR imaging morphometry and PET were largely overlapping in value for discrimination. Baseline MR imaging and PET measures were more predictive of clinical change in MCI than were CSF measures.

[1]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[2]  B. Reisberg,et al.  Computed Tomography and Positron Emission Transaxial Tomography Evaluations of Normal Aging and Alzheimer's Disease , 1983, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[3]  J. Hanley,et al.  A method of comparing the areas under receiver operating characteristic curves derived from the same cases. , 1983, Radiology.

[4]  C. Reynolds,et al.  Wechsler memory scale-revised , 1988 .

[5]  Robert A. Bornstein,et al.  The Wechsler Memory Scale—Revised , 1990 .

[6]  A. Dale,et al.  Improved Localizadon of Cortical Activity by Combining EEG and MEG with MRI Cortical Surface Reconstruction: A Linear Approach , 1993, Journal of Cognitive Neuroscience.

[7]  K. Blennow,et al.  Tau protein in cerebrospinal fluid: a biochemical marker for axonal degeneration in Alzheimer disease? , 1995, Molecular and chemical neuropathology.

[8]  N. Foster,et al.  Preserved Pontine Glucose Metabolism in Alzheimer Disease: A Reference Region for Functional Brain Image (PET) Analysis , 1995, Journal of computer assisted tomography.

[9]  Alan C. Evans,et al.  A nonparametric method for automatic correction of intensity nonuniformity in MRI data , 1998, IEEE Transactions on Medical Imaging.

[10]  A. Dale,et al.  High‐resolution intersubject averaging and a coordinate system for the cortical surface , 1999, Human brain mapping.

[11]  Anders M. Dale,et al.  Cortical Surface-Based Analysis I. Segmentation and Surface Reconstruction , 1999, NeuroImage.

[12]  E. Yeterian,et al.  MRI-Based Topographic Parcellation of Human Cerebral White Matter and Nuclei II. Rationale and Applications with Systematics of Cerebral Connectivity , 1999, NeuroImage.

[13]  A. Dale,et al.  Cortical Surface-Based Analysis II: Inflation, Flattening, and a Surface-Based Coordinate System , 1999, NeuroImage.

[14]  A M Dale,et al.  Measuring the thickness of the human cerebral cortex from magnetic resonance images. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[15]  A. Convit,et al.  Hippocampal formation glucose metabolism and volume losses in MCI and AD , 2001, Neurobiology of Aging.

[16]  A. Dale,et al.  Whole Brain Segmentation Automated Labeling of Neuroanatomical Structures in the Human Brain , 2002, Neuron.

[17]  M H Buonocore,et al.  Brain structure and cognition in a community sample of elderly Latinos , 2002, Neurology.

[18]  William J Jagust,et al.  Brain function and cognition in a community sample of elderly Latinos , 2002, Neurology.

[19]  Kaj Blennow,et al.  β-Amyloid (Aβ) protein in cerebrospinal fluid as a biomarker for Alzheimer’s disease , 2002, Peptides.

[20]  E. Barrett-Connor,et al.  Serum lipoprotein levels, statin use, and cognitive function in older women. , 2002, Archives of neurology.

[21]  K. Blennow,et al.  Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease. , 2002, Peptides.

[22]  A. Dale,et al.  Regional and progressive thinning of the cortical ribbon in Huntington’s disease , 2002, Neurology.

[23]  Marianna D. Eddy,et al.  Regionally localized thinning of the cerebral cortex in schizophrenia , 2003, Schizophrenia Research.

[24]  Nikos Makris,et al.  Automatically parcellating the human cerebral cortex. , 2004, Cerebral cortex.

[25]  A. Dale,et al.  Thinning of the cerebral cortex in aging. , 2004, Cerebral cortex.

[26]  Yaakov Stern,et al.  PET Network Abnormalities and Cognitive Decline in Patients with Mild Cognitive Impairment , 2006, Neuropsychopharmacology.

[27]  M. D. de Leon,et al.  Hypometabolism exceeds atrophy in presymptomatic early-onset familial Alzheimer's disease. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[28]  Anders M. Dale,et al.  An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest , 2006, NeuroImage.

[29]  B. Reisberg,et al.  Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment , 2006, Neurobiology of Aging.

[30]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.

[31]  Anders M. Dale,et al.  Reliability in multi-site structural MRI studies: Effects of gradient non-linearity correction on phantom and human data , 2006, NeuroImage.

[32]  Henrik Zetterberg,et al.  Erratum: Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: A follow-up study (Lancet Neurology (2006) 5 (228-34)) , 2006 .

[33]  K. Blennow,et al.  Imaging and CSF Studies in the Preclinical Diagnosis of Alzheimer's Disease , 2007, Annals of the New York Academy of Sciences.

[34]  J. Trojanowski,et al.  Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics , 2007, Nature Reviews Drug Discovery.

[35]  S. Santi,et al.  Early detection of Alzheimer’s disease using neuroimaging , 2007, Experimental Gerontology.

[36]  K. Walhovd,et al.  Morphometric Changes in the Episodic Memory Network and Tau Pathologic Features Correlate with Memory Performance in Patients with Mild Cognitive Impairment , 2008, American Journal of Neuroradiology.

[37]  J. Baron,et al.  Relationships between Hippocampal Atrophy, White Matter Disruption, and Gray Matter Hypometabolism in Alzheimer's Disease , 2008, The Journal of Neuroscience.

[38]  E. Reiman,et al.  Multicenter Standardized 18F-FDG PET Diagnosis of Mild Cognitive Impairment, Alzheimer's Disease, and Other Dementias , 2008, Journal of Nuclear Medicine.

[39]  A. Verma,et al.  Amyloid, hypometabolism, and cognition in Alzheimer disease: An [11C]PIB and [18F]FDG PET study , 2008 .

[40]  Nick C Fox,et al.  Amnestic Mild Cognitive Impairment: Structural MR Imaging Findings Predictive of Conversion to Alzheimer Disease , 2008, American Journal of Neuroradiology.

[41]  et al.,et al.  Categorical and correlational analyses of baseline fluorodeoxyglucose positron emission tomography images from the Alzheimer's Disease Neuroimaging Initiative (ADNI) , 2009, NeuroImage.

[42]  C. Jack,et al.  MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers , 2008, Brain : a journal of neurology.

[43]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[44]  Norbert Schuff,et al.  Alzheimer’s Disease Neuroimaging Initiative: A one-year follow up study using Tensor-Based Morphometry correlating degenerative rates, biomarkers and cognition , 2009 .

[45]  Anders M. Fjell,et al.  Multimodal imaging in mild cognitive impairment: Metabolism, morphometry and diffusion of the temporal–parietal memory network , 2009, NeuroImage.

[46]  Christos Davatzikos,et al.  Baseline and longitudinal patterns of brain atrophy in MCI patients, and their use in prediction of short-term conversion to AD: Results from ADNI , 2009, NeuroImage.

[47]  Michael Weiner,et al.  Mapping correlations between ventricular expansion and CSF amyloid and tau biomarkers in 240 subjects with Alzheimer's disease, mild cognitive impairment and elderly controls , 2009, NeuroImage.

[48]  A. Dale,et al.  Alzheimer disease: quantitative structural neuroimaging for detection and prediction of clinical and structural changes in mild cognitive impairment. , 2009, Radiology.

[49]  Henrik Zetterberg,et al.  Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease , 2009, Neurobiology of Aging.

[50]  A. Dale,et al.  Structural MRI biomarkers for preclinical and mild Alzheimer's disease , 2009, Human brain mapping.

[51]  A. Dale,et al.  Multi-modal imaging predicts memory performance in normal aging and cognitive decline , 2010, Neurobiology of Aging.

[52]  Frederik Barkhof,et al.  Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study , 2010, Neurobiology of Aging.

[53]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease: Report of the NINCDS—ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease , 2011, Neurology.